Available Technologies
# of Displayed Technologies: 10 / 13
Applied Category Filter (Click To Remove): Antibodies
Anti-GARP monoclonal antibody enhances anti-cancer therapeutics
TS-075242 — THE PROBLEM
Although immune checkpoint blockade (ICB) has emerged as promising cancer immunotherapy, many tumors fail to respond to ICB. This failed response is often driven by the activation of TGF-β1 in the tumor microenvironment (TME), which induces regulatory T cells and inhibits the funct…
- College: College of Medicine (COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
Lipolysis-stimulated lipoprotein receptor (LSR)-targeted mAb and ADC for LSR+ tumors treatment
TS-075185 — Problem
The lipolysis-stimulated lipoprotein receptor (LSR) is a promising target for cancer therapy. LSR is overexpressed in many tumor tissues with metastatic signatures such as breast, gastric, and endometrial cancer. LSR expression levels may serve as prognostic indicators and help stratify pat…
- College: College of Engineering (COE)
- Inventors: Liu, X. Margaret; Zhou, Lufang; Zhou, Zhuoxin
- Licensing Officer: Schworer, Adam
Cancer mitochondria-targeted luminoptogenetics (mLumiOpto) to treat GBM and metastatic cancers
TS-075179 — Problem
Mitochondria is a promising target for cancer treatment. However, current strategies to specifically and effectively destroy cancer mitochondria in vivo are limited.
Solution
Applications
Competitive Advantages
Seeking Opportunities for Licensing and collaboration
- College: College of Engineering (COE)
- Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
- Licensing Officer: Schworer, Adam
Novel Antibodies Targeting IL-2 for Treatment of Cancer
TS-075174 — Problem
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Treatments activating effector cells against tumors are undermined by an autoinhibitory loop caused by endogenous IL-2 secreted from activated Teffs. …
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Willson, Christopher
Humanized somatostatin receptor 2 (SSTR2) mAb and ADCs to target SSTR2+ tumors
TS-075165 — Problem
Neuroendocrine tumors (NETs) are often metastatic at diagnosis, thus limiting surgical options. Chemotherapies offer limited efficacy and high toxicity. Meningiomas, though usually benign, are the most common intracranial tumors. Both NETs and meningiomas overexpress SSTR2, making it a prom…
- College: College of Engineering (COE)
- Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
- Licensing Officer: Schworer, Adam
A new modular format for bispecific antibody fragments
TS-068425 — Functionalization of scFvs with cyclic peptide linkers
The Need
The high specificity of antibodies has been utilized to develop numerous technologies, tools and therapeutics, like ADCs and radiopharmaceuticals. Engineered antibody fragments like single-chain variable fragments (scFvs) are starting to see their way into the clinic in BiTEs and CAR T. Sc…
- College: College of Arts and Sciences (COAAS)
- Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
- Licensing Officer: Panic, Ana
Humanized SSTR2 mAb and ADC to target SSTR2+ tumors
TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment
The Liu Lab
Dr. Xiaoguang “Margaret” Liu applies her industry experience (Lonza, Merck, and Life Technologies) in cell line and process development towards her lab’s focus on targeted anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates, and gene therapi…
- College: College of Engineering (COE)
- Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
- Licensing Officer: Schworer, Adam
Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Willson, Christopher
Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
- College: College of Medicine (COM)
- Inventors: Chu, Nam; Le, Nhat
- Licensing Officer: Willson, Christopher
Addressing the Challenges in Cancer Imaging
TS-062545 — The Need: Addressing the Challenges in Cancer Imaging
Cancer continues to be a major cause of global mortality, with over 10% of all deaths attributed to this devastating disease. Despite significant advancements in cancer research, there remains a critical need to enhance current techniques for pr…
- College: College of Arts and Sciences (COAAS)
- Inventors: Magliery, Thomas; Long, Nicholas; Sullivan, Brandon
- Licensing Officer: Panic, Ana
